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Nesfatin-1, the N-terminal fragment of nucleobindin 2 (NUCB2), is an 82 amino-acid
peptide that inhibits food intake and exerts weight-reducing effects. Nesfatin-1 has been
proposed as a potential anti-obesity peptide. However, studies to date have mainly
focused on the acute satiety effects of centrally administered nesfatin-1. The main
objective of our studies was to characterize the long-term/chronic effects of peripheral
administration of nesfatin-1 on whole-body energy balance and metabolic partitioning in
male Fischer 344 rats. Short-term (1 day) subcutaneous infusion of nesfatin-1 (50µg/kg
bodyweight/day) using osmoticmini-pumps increased spontaneous physical activity and
whole-body fat oxidation during the dark phase. This was accompanied by decreased
food intake and basal metabolic rate compared to saline infused controls. On the seventh
day of nesfatin-1 infusion, cumulative food intake, and total spontaneous physical activity
during the dark phase were significantly reduced and elevated, respectively. Meanwhile,
intraperitoneal injection of nesfatin-1 only caused a dark phase specific reduction in food
intake and an increase in physical activity. NUCB2 mRNA expression in the brain and
stomach, as well as serum NUCB2 concentrations were significantly reduced after 24 h
fasting, while a post-prandial increase in serum NUCB2 was found in ad libitum fed rats.
Collectively, our results indicate that chronic peripheral administration of nesfatin-1 at the
dose tested, results in a sustained reduction in food intake and modulation of whole body
energy homeostasis.
Keywords: nesfatin-1, food intake, body weight, physical activity, energy expenditure, osmotic mini-pumps,
metabolism, rats
Introduction
Nesfatin-1 (NEFA/nucleobindin 2-Encoded Satiety-and FAT-Influencing protein-1) is an 82 amino
acid cleavage product of the precursor protein nucleobindin 2 (NUCB2) (Oh-I et al., 2006). NUCB2
is expressed in the hypothalamic paraventricular nucleus (PVN), arcuate nucleus (ARC), lateral
hypothalamus (LH), supraoptic nucleus (SON), and zona incerta (ZI) along with the nucleus of
the solitary tract (NTS) in rodents. Nesfatin-1 was also found in rat cerebrospinal fluid (Oh-I
et al., 2006). In addition to hypothalamus nuclei and NTS, NUCB2 positive cells were local-
ized in the brain stem regions consisting of Edinger Westphal (EW), dorsal motor of nucleus
of vagus (DMNV), and caudal raphe nuclei of rats (Oh-I et al., 2006; Brailoiu et al., 2007;
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Foo et al., 2008). Double-labeling immunohistochemistry
revealed that NUCB2 staining cells co-localize with vaso-
pressin, oxytocin, cocaine and amphetamine regulated transcript
(CART), and melanin concentrating hormone (MCH) (Kohno
et al., 2008). Cholecystokinin (CCK) activates NUCB2 neurons
in the PVN and NTS through a corticotropin-releasing factor
(CRF)2-receptor-dependent pathway (Stengel et al., 2009). The
presence of NUCB2 in brain regions known to regulate energy
balance and body weight (Oh-I et al., 2006; Brailoiu et al., 2007;
Foo et al., 2008) suggest a possible role for NUCB2 derived
peptides in the regulation of energy balance.
In agreement with this notion, several studies have indi-
cated that nesfatin-1 has anorectic effects in rats and mice. In
fact, intracerebroventricular injection of nesfatin-1 reduces dark
phase feeding and overall body weight in a dose dependent
manner (Oh-I et al., 2006; Stengel et al., 2009; Gonzalez et al.,
2011; Wernecke et al., 2014). The satiety induced by nesfatin-1
was found independent of leptin, however, central administra-
tion of alpha-MSH has been shown to increase NUCB2 mRNA
expression in the hypothalamus (Oh-I et al., 2006). It was also
shown that only nesfatin-1, not nesfatin-2 or 3, the other two
fragments of NUCB2 exerts anorectic effects in rodents (Oh-
I et al., 2006). Similar to the effects seen in response to cen-
tral administration, intraperitoneal injections of nesfatin-1 also
caused a remarkable suppression of food intake in lean and
obese mice (Shimizu et al., 2009). However, this effect lasted
for only 1 h after injection. It was followed by an increase in
food intake in nesfatin-1 treated animals. Peripheral administra-
tion of nesfatin-1 reduced nocturnal food intake in rats (Sten-
gel et al., 2009; Gonzalez et al., 2011; Wernecke et al., 2014).
The satiety effects of nesfatin-1 are blocked by the co-injection
of CRF-receptor antagonists, suggesting that nesfatin-1 may act
through hypothalamic CRF (Stengel et al., 2009). Nesfatin-1
crosses the blood-brain barrier (BBB) without saturation, which
could be of clinical significance for its use as a pharmacological
agent for obesity treatment (Pan et al., 2007; Price et al., 2007).
These findings suggest central effects of nesfatin-1 in regulating
metabolism.
There are several reports available now indicating the
metabolic effects of nesfatin-1 in rats and mice (Gonzalez et al.,
2012; Mohan and Unniappan, 2013). However, most of these
experiments were restricted to short-term, central effects of
nesfatin-1 on food intake (Oh-I et al., 2006; Shimizu et al.,
2009; Stengel et al., 2009, 2012; Atsuchi et al., 2010; Yosten and
Samson, 2010; Goebel et al., 2011; Chen et al., 2012; Konczol
et al., 2012; Gotoh et al., 2013; Wernecke et al., 2014). Some
exceptions are Shimizu et al. (2009) and Dong et al. (2014), who
employed peripheral injections to administer nesfatin-1. Li et al.
(2013) examined the effects of continuous peripheral infusion
of nesfatin-1 on glucose homeostasis, food intake, and body
weight. We provided the first comprehensive metabolic profil-
ing of peripherally administered nesfatin-1 effects in rats (Gon-
zalez et al., 2011). However, this study also just monitored the
effects of nesfatin-1 for 5 h post-infusion during the dark phase.
Given the short half-life of nesfatin-1 in circulation (Pan et al.,
2007; Price et al., 2007), acute peripheral injections may not suffi-
ciently induce nesfatin-1 related metabolic functions in rodents.
In addition, from a therapeutic perspective, continuous periph-
eral administration of nesfatin-1 would be the preferred mode
of delivery for the treatment for metabolic diseases, especially
obesity. To the best of our knowledge, there are no reports on
the chronic effects of peripherally administered nesfatin-1 on
energy balance. This study extends our own previous findings,
and tests a previously unknown aspect of nesfatin-1 effects on
energy balance. Using automated metabolic cages, we carried out
an in-depth and comprehensive analysis of the metabolic effects
of continuous peripheral administration of nesfatin-1 in lean rats.
While our results confirm the previously known anorectic effects
of nesfatin-1, it also provides novel information on sustained
effects of nesfatin-1 on whole body energy homeostasis. Circulat-
ing levels of nesfatin-1/NUCB2 increased post-meal, indicating a
meal responsive secretion of thismetabolic hormone. In addition,
we found that fasting reduces NUCB2 mRNA expression in the
brain and stomach and reduces circulating levels of nesfatin-1,
while re-feeding reverses these changes.
Materials and Methods
Animals
Unless otherwise specified, age and weight (∼200 g) matched
lean, male Fischer 344 rats purchased from Charles River Lab-
oratories Inc. (Saint-Constant, Quebec, Canada) were used for
all studies. Research protocols used in this study adhered to the
guidelines of the Canadian Council for Animal Care and was
approved by the York University Animal Care Committee (Pro-
tocol number 2007-5). Rats were individually housed in polycar-
bonate cages with bedding in a 12 h light (0700–1900 h):12 h dark
(1900–0700 h) photoperiod at 23± 1◦C and controlled humidity
at the York University vivarium. Animals had ad libitum access to
tap water and normal rat chow (PurinaMills, St. Louis, Missouri).
Materials
The 82 amino acid rat nesfatin-1 (VPIDVDKTKVHNVEPVE
SARIEPPDTGLYYDEYLKQVIEVLETDPHFREKLQKADIEEIR
SGRLSQELDLVSHKVRTRLDEL) was synthesized by Abgent
Technologies (San Diego, California) and was purchased through
MJS Biolynx (Toronto, Ontario, Canada). Synthetic nesfatin-1
was HPLC purified to 95% purity, and the mass and purity were
confirmed by mass spectrometry. Nesfatin-1 was freshly pre-
pared by dissolving in 0.9% sterile saline (0.9% sodium chloride)
for each study and the resuspended peptide never underwent
freeze-thaw cycles. Sterile saline was purchased from Medical
Mart Inc. (Toronto, Ontario, Canada). One-day (Model 2001D)
and 7-day (Model 2ML1) Alzet™ osmotic mini-pumps were
purchased from Durect Corporation (Cupertino, California).
Animal Acclimation, Surgery, and Monitoring
It has been shown that acclimation is critical in reducing han-
dling stress, and in obtaining consistent results on food intake
(Abbott et al., 2006). The acclimation protocol used here was
validated for our research, and was reported earlier (Unniappan
et al., 2006; Unniappan and Kieffer, 2008; Gonzalez et al., 2011).
Briefly, rats were housed in polycarbonate cages for 7 days from
the day of arrival and then routinely handled for 7 days before
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starting the experiment. From the first day of acclimation, ani-
mals were transported to the surgery room, gently handled for
several minutes and returned to their respective cages. On day
3 of acclimation, rats were anesthetized using 3% isoflurane and
oxygen as the gaseous carrier and shaved in the area where the
implantation was to be made. On the implantation day, weight
matched rats (∼200 g) were anesthetized, a small sub-clavicular
incision made and osmotic mini-pumps were implanted sub-
cutaneously. Following implantation, wounds were immediately
sealed using wound clips (VWR, Canada) and antiseptics were
applied using cotton swabs. Rats were then removed from the
anesthetic machine, weighed and returned to their cages and
allowed to recover from anesthesia in their cages. For auto-
mated monitoring of feeding and other parameters, animals were
transferred to the Comprehensive Laboratory Animal Monitor-
ing System (CLAMS; Columbus Instruments, Ohio) cages. Prior
tomonitoring in vivometabolic variables, the CLAMS gas sensors
and balances were calibrated followingmanufacturer’s guidelines.
After implantation of the pumps (always completed an hour
before the dark phase), the animals were placed in CLAMS cages
equipped to provide continuous automated monitoring of water
and food intake as well as locomotor activity. Each cage was
also connected to an open-circuit calorimeter for determination
of oxygen consumption (VO2), CO2 production (VCO2), res-
piratory quotient (RQ), and energy expenditure (EE). Animals
were allowed to acclimate to the CLAMS cages for an hour post-
surgery and following this, all variables were recorded for 24 h
(1800–1900 h next day).
The equations used for all calculations are provided in the
Columbus Instruments website (http://www.colinst.com/brief.
php?id=51). RQ was calculated by dividing VCO2 by VO2 with
values ranging from 0.7 to 1.0. A shift of RQ values toward 0.7
indicates that fatty acids contribute the most to energy produc-
tion, while a shift toward 1.0 indicates that carbohydrates are
the main substrates used. EE was determined using the following
equation: EE = CV ∗ VO2, where the calorific value is multi-
plied by VO2. CV was determined using the following equation:
CV = (3.815 + 1.232) ∗ RQ. Each cage is also equipped with a
system of infrared beams that detects animal movement in the
X (the length of the cage) and Z (the height of the cage) axes.
The energy derived from carbohydrates and fats were extrapo-
lated from the heat/liter data obtained from CLAMS, using the
methods of McLean and Tobin, as described in the protocols pro-
vided by Columbus Instruments. The activities were presented as
total horizontal (X-TOT), ambulatory (X-AMB, which refers to
successive beam breaks in the X axis), and total vertical (Z-TOT)
movements. Acclimated rats were used in all studies and same
rats were never used for more than one study.
Assessment of Metabolic Effects of Short-Term
(1 day) Continuous Infusion of Nesfatin-1
Fischer 344 rats (n = 4/group; study repeated twice) were accli-
mated and implanted with osmotic mini-pumps containing syn-
thetic rat nesfatin-1 (50µg/kg body weight/day) or saline and
weremonitored using CLAMS as described above.We conducted
pilot studies where nesfatin-1 at doses 1, 10, 50, and 100µg/kg
body weight/day were infused using osmotic mini-pumps to
male Fischer 344 rats. From these studies, we selected a dose
(50µg/kg body weight/day or∼5 nmol/kg BW/day) of nesfatin-1
that was effective in reducing food intake (Gonzalez et al., 2011).
The dose of nesfatin-1 tested here is lower compared to the 0.5
and 1.25 nmol/g doses of nesfatin-1 used earlier in an intraperi-
toneal injection study (Shimizu et al., 2009). The experiment
was repeated twice using different sets of rats, with same results
obtained. A representative set of data from one experiment (n =
4 rats/group) is provided here.
Evaluation of Metabolic Effects of Long-Term (7
day) Continuous Infusion of Nesfatin-1
To test the long-term effects of nesfatin-1 on rats, in a separate
study, a 7-day continuous infusion of nesfatin-1 was employed.
Rats (n = 4/group; study repeated twice) were implanted with
7-day osmotic mini-pumps infusing 50µg/kg body weight/day
of nesfatin-1. Daily cumulative food intake and body weight
were manually determined daily. Using the CLAMS, complete
metabolic activities of the saline (control, n = 4) and nesfatin-1-
infused (n = 4) rats were measured over 24 h (1800–1800 h next
day) on days 6–7 during the course of a 7-day infusion-period.
This experiment was also repeated twice, and representative data
(n = 4 rats/group) from one experiment are provided.
Effects of Acute Administration of Nesfatin-1 on
Whole Body Energy Homeostasis
Rats (n = 4/group) were intraperitoneally (i.p.) injected with,
200µL of 0.9% sterile saline (sodium chloride, control) or
50µg/kg body weight/day of nesfatin-1 dissolved in sterile saline,
using a 27-gauge needle attached to a 1mL syringe (Becton-
Dickinson, Ontario, Canada). CLAMS measurements were con-
ducted as described earlier.
Investigations on the Effects of Feeding Status of
Rats on NUCB2 mRNA expression in the Brain
and Stomach
Since nesfatin-1 is an anorexigen (Oh-I et al., 2006), it is possible
that the NUCB2 mRNA display a meal-regulated pattern in its
expression in the brain and stomach, two major tissue sources of
NUCB2/nesfatin-1. NUCB2 immunoreactivity has been reported
in a large number of brain regions (Oh-I et al., 2006; Brailoiu
et al., 2007; Foo et al., 2008; Kohno et al., 2008; Stengel et al.,
2008; Goebel et al., 2009), therefore, total RNA was extracted
from whole brain. To determine whether NUCB2 mRNA expres-
sion is altered during fasting, brain and stomach tissues were col-
lected from ad libitum fed rats, and rats deprived of food for 24 h.
Briefly, animals were euthanized by inhalation of an overdose of
isoflurane, followed by cervical dislocation. Brain (whole tissue),
and stomach (whole stomach) were removed, immediately frozen
in liquid nitrogen, and then stored at −80◦C until total RNA
was extracted using TRIzol™ Reagent (Invitrogen Canada Inc.,
Ontario, Canada) or Aurum total RNA kit (Bio-Rad laboratories
Inc., Ontario, Canada) according to the manufacturer’s instruc-
tions. Optical density readings at 260 nmweremade to determine
the total RNA concentration of each tissue sample using spec-
trophotometer (MultiSKAN SPECTRON, Thermo Fisher Sci-
entific Inc., Canada). RNA purity was determined through the
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260/280 OD ratio. Total RNA was stored at −80◦C. cDNA
was synthesized using iScript cDNA synthesis kit (Bio-Rad lab-
oratories, Inc. Ontario, Canada) based on the manufacturer’s
instructions and were kept at −20◦C until used for quantita-
tive real-time (qRT) PCRs. For quantification, rat NUCB2 for-
ward primer (5′-GCTG TTCCTATTGATGTGG-3′) and reverse
primer (5′-CTTCCTACTTCTTGCCTC-3′) were used.
Effects of the Feeding Status on Serum
Nesfatin-1/NUCB2 Levels
If nesfatin-1 is indeed an endogenous anorexigen, we should see
an increase in circulating levels of nesfatin-1 following ameal and
a decrease under fasting conditions. In order to determine any
meal related changes in circulating nesfatin-1/NUCB2, we col-
lected serum samples from ad libitum fed rats and rats deprived
of food for 24 h. In addition, serum was also collected from rats
an hour prior to the commencement of their feeding (1800 h) and
3 h after starting their active feeding (2200 h). Nesfatin-1/NUCB2
ELISA was conducted as described previously by us (Gonzalez
et al., 2011).
Statistical Analyzes
Statistical analyses for quantitative real-time PCR, CLAMS stud-
ies, and tissue mass comparison were conducted using Two-Way
ANOVA followed by Newman-Keuls post-test (GraphPad Prism
4, San Diego, USA). Mann-Whitney test or Student’s t-tests were
used for testing groups within the CLAMS, mRNA expression
and ELISA data. Significance was considered at P < 0.05. Data
are expressed as mean+ SEM.
Results
Short-Term (1 Day) Nesfatin-1 Treatment Caused
Dark-Phase Specific Metabolic Changes
When compared to controls, nesfatin-1 treatment elicited
a significant reduction in cumulative food intake during
the 12-h dark phase (Figure 1A). The average feeding bout
FIGURE 1 | Cumulative food intake (mg/g BW; A) and average
feeding bout size (mg/g BW; B) decreased in rats continuously
infused with 50µg/kg body weight/day nesfatin-1 for 1 day. An
increase in locomotor activity (beam breaks/12 h; C–F) was also
observed during the dark phase of nesfatin-1 infusion. The activities
were presented as total horizontal (X-TOT), ambulatory (X-AMB, which
refers to successive beam breaks in the X axis), and vertical (Z-TOT)
movements. Dark cycle occurred during 1900 to 0700 h, while the light
cycle was from 0700 to 1900 h next day. All data are presented as
means ± SEM with an n = 4 rats/group. *P < 0.05 compared to control.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 April 2015 | Volume 3 | Article 22
Mortazavi et al. Nesfatin-1 modulates metabolism of rats
size was significantly lower for nesfatin-1 treated animals
compared to saline treated controls in both dark and light
phases (Figure 1B). Total (Figure 1C), ambulatory (Figure 1D),
horizontal (Figure 1E) and vertical (Figure 1E) activities of
nesfatin-1 treated rats were significantly higher than control
group during the dark phase. The spontaneous physical activ-
ity was not different in nesfatin-1-treated and control ani-
mals during the light phase (Figures 1C–F). The total num-
ber of feeding bouts was not significantly different between
treated and untreated animals (Supplemental Figure 1A). No
change in cumulative water intake was observed between
nesfatin-1 treated and control animals (Supplemental Fig-
ure 1B). There were no significant differences in the body
weight of nesfatin-1 treated and control animals (Supplemental
Figure 1C).
Average RQ of nesfatin-1 treated rats showed significant
reduction in comparison with controls in both dark and
light phases (Figure 2A). The relative contribution of fatty
acids toward total energy production was significantly higher
in nesfatin-1 treated rats during both dark and light phases
(Figure 2B). On the other hand, carbohydrate oxidation was
significantly reduced during the dark phase alone (Figure 2C).
Oxygen consumption (VO2) was significantly lower in nesfatin-
1 treated rats during the dark phase (Figure 2D), and CO2
production was also reduced in nesfatin-1 treated rats com-
pared to the saline controls during the dark and light phases
(Figure 2E). No change in total energy expenditure was
observed between nesfatin-1 treated animals and saline controls
(Figure 2F).
Long-Term Nesfatin-1 Treatment Resulted in
Lowering of Food Intake and an Increase in
Physical Activity
On the last day (day 7) of continuous infusion of nesfatin-1,
cumulative food intake during the dark phase was significantly
reduced compared to the controls (Figure 3A). Similar to
the short-term study, the average size of feeding bouts was
significantly smaller in nesfatin-1 treated animals compared
FIGURE 2 | Respiratory quotient (RQ; A) and relative contribution of
fatty acids (B) and carbohydrates (C) to energy expenditure, average
O2 consumption (D) and CO2 production (E) were altered during 1
day continuous infusion of nesfatin-1. No changes in energy expenditure
(F) were observed during the treatment. The dark cycle occurred from 1900
to 0700 h, while the light cycle was from 0700 to 1900 h next day. Data are
represented as means ± SEM with an n = 4 rats/group. *P < 0.05,
**P < 0.01 compared to control.
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FIGURE 3 | Cumulative food intake (mg/g BW; A) and average feeding
bout size (mg/g BW; B) of rats remained reduced on the seventh day of
continuous infusion with nesfatin-1. Increases in locomotor activity were
also observed in nesfatin-1 treated animals (beam breaks/12 h; C–F) during
the seventh day of continuous infusion. The activities were presented as total
horizontal (X-TOT), ambulatory (X-AMB, which refers to successive beam
breaks in the X axis), and vertical (Z-TOT) movements. Dark cycle occurred
during 1900 to 0700 h, while the light cycle was from 0700 to 1900 h next
day. All data are presented as means ± SEM with an n = 4 rats/group.
*P < 0.05 compared to control, and **P < 0.01 compared to controls.
to controls during the dark phase (Figure 3B). Total activ-
ity (XTOT + ZTOT) remained significantly higher (∼32%)
for nesfatin-1 treated animals compared to saline treated con-
trols (Figure 3C). Similarly, total ambulatory activity (XAMB)
on the seventh day of infusion remained higher (∼56%) in
nesfatin-1 treated rats than control rats (Figure 3D). Nesfatin-
1 treated rats experienced higher (∼32%) than control noc-
turnal total horizontal activity on the seventh day of contin-
uous infusion (Figure 3E). The number of dark phase feed-
ing bouts of nesfatin-1 treated rats was not different than
saline control rats on the seventh day of infusion (Sup-
plemental Figure 2A). No differences were found in the
water intake (Supplemental Figure 2B), total vertical activ-
ity (Figure 3F), and body weight (Supplemental Figure 2C) of
saline treated and nesfatin-1 treated rats after 7 days of chronic
infusion.
The RQ of nesfatin-1 treated rats were not different from
control rats at the end of the 7-day-nesfatin-1-infusion period
(Figure 4A). The relative contribution of either carbohydrates or
fatty acids toward energy production in nesfatin-1 treated rats
was not statistically different between groups on the seventh day
of the infusion period (Figures 4B,C). Interestingly, both average
O2 consumption and average CO2 production decreased during
the light phase for nesfatin-1 treated rats during the seventh day
of infusion (Figures 4D,E). We observed a significant reduction
in energy expenditure during the light phase in nesfatin-1-
treated animals (Figure 4F) compared to saline treated con-
trols. However, the total energy expenditure of nesfatin-1
treated rats during the dark phase was same as in control rats
(Figure 4F).
Acute Administration of Nesfatin-1 Decreases
Food Intake and Increases Physical Activity
during the Dark Phase
Intraperitoneal injection of nesfatin-1 caused a dark phase spe-
cific reduction in food intake (Figure 5A), and physical activity
(Figures 5C–F). Unlike the day 1 and day 7 results, nesfatin-1
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FIGURE 4 | Respiratory quotient (A) and relative contribution of
fatty acids (B) and carbohydrates (C) to energy expenditure
was not altered on day 7 of continuous infusion of
nesfatin-1. However, the effect of nesfatin-1 on average O2
consumption (D), CO2 production (E), and energy expenditure (F)
was reduced during the light phase of the seventh treatment day.
The dark cycle in each panel occurred from 1900 to 0700 h, while
the light cycle was from 0700 to 1900 h next day. Data are
represented as means ± SEM with an n = 4 rats/group. *P < 0.05,
**P < 0.01 compared to control.
was found to have no effects on othermetabolic parameters tested
(Figures 5B, 6A–F).
NUCB2 mRNA Expression was Reduced during
Fasting and Increased after Re-Feeding, while
Serum Nesfatin-1/NUCB2 Levels are elevated
after a Post-Meal, and Reduced after Food
Deprivation
Compared to the expression levels in ad libitum fed con-
trols, NUCB2 mRNA expression in the brain and stomach was
significantly reduced (∼60%) after food deprivation for 24 h
(Figure 7A). Re-feeding for 3 h after the 24-h food depriva-
tion resulted in a return of brain NUCB2 mRNA expression
to that in the brain of fed rats (Figure 7A). Serum nesfatin-
1/NUCB2 levels in rats deprived of food for 24 h were signifi-
cantly lower compared to that in ad libitum fed rats (Figure 7B).
Levels of circulating nesfatin-1/NUCB2 significantly increased
upon feeding (at 2200 h; 3 h after commencing the dark
phase), compared to that found at a time immediately prior
to the dark phase (at 1800 h; final hour of the light phase)
(Figure 7C).
Discussion
While some of the research reported here are confirmatory,
it also provides insights on several previously uncharacterized
aspects of nesfatin-1 on metabolism in rats. We report here that
peripherally administered nesfatin-1 causes a sustained reduc-
tion in food intake in Fischer 344 rats. Continuous, peripheral
(sub-cutaneous) infusion of nesfatin-1 significantly reduced food
intake during the dark phase in our short-term (1 day). These
results obtained using automated metabolic cages that avoided
potential effects of human interference, confirms previous find-
ings on the anorectic actions, especially dark phase specific food
intake reducing actions of nesfatin-1 in rodents (Oh-I et al., 2006;
Shimizu et al., 2009; Gonzalez et al., 2011; Konczol et al., 2012;
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FIGURE 5 | Cumulative food intake (mg/g BW; A) was
significantly reduced, but the average feeding bout size (mg/g
BW; B) was not influenced by nesfatin-1 during the dark phase.
Increases in locomotor activity were also observed in nesfatin-1 treated
animals (beam breaks/12 h; C–F) during the dark phase. The activities
were presented as total horizontal (X-TOT), ambulatory (X-AMB, which
refers to successive beam breaks in the X axis), and vertical (Z-TOT)
movements. Dark cycle occurred during 1900 to 0700 h, while the
light cycle was from 0700 to 1900 h next day. All data are presented
as means ± SEM with an n = 4 rats/group. *P < 0.05 compared to
control, **P < 0.01 compared to control, ***P < 0.001 compared to
control.
Wernecke et al., 2014). Further, our results indicate that nesfatin-
1 sustain its anorectic effect during a 7 day infusion period.
While we did not see any differences in the duration of feed-
ing bouts, nesfatin-1 treatment caused a reduction in the average
bout size. The net reduction in food intake is likely achieved by
the cumulative reductions in feeding bouts during the dark phase.
It was reported that nesfatin-1 crosses the BBB in a bidirectional
manner (Pan et al., 2007; Price et al., 2007). Therefore, it is possi-
ble that peripherally administered nesfatin-1 reaches the brain to
elicit its effects. In addition, it was demonstrated that nesfatin-1
can activate vagal afferent neurons by stimulating calcium influx
through N-type channels, thus conveying an indirect mecha-
nism by which peripheral nesfatin-1 can relay a satiety signal
to the brain (Iwasaki et al., 2009). Previous research has shown
that nesfatin-1 can remain stable in the serum for a period of
10min (Price et al., 2007), although Pan et al. (2007) have shown
that nesfatin-1 has a relatively long half-life of ∼20min in both
blood and brain. Furthermore, nesfatin-1 diffuses bi-directionally
through the BBB using a non-saturable mechanism (Pan et al.,
2007; Price et al., 2007). It is also likely that nesfatin-1 inhibits
feeding and influences feeding behavior by affecting gut motility
and transit time. However, further studies are required to explore
these possibilities.
The reason for the transient dark phase satiety effects of
nesfatin-1 is also not completely understood, although, previ-
ous studies have shown that nesfatin-1-induced satiety is not
due to taste aversion (Shimizu et al., 2009). Stengel et al. (2009)
provides pharmacological evidence that the nesfatin-1 induced
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FIGURE 6 | Respiratory quotient (A) and relative contribution
of fatty acids (B) and carbohydrates (C) to energy
expenditure, average O2 consumption (D), CO2 production
(E), and energy expenditure (F) were not altered as a
result of nesfatin-1 infusion. The dark cycle in each panel
occurred from 1900 to 0700 h, while the light cycle was from
0700 to 1900 h next day. Data are represented as means ±
SEM with an n = 4 rats/group.
dark-phase inhibition of feeding is mediated by the activation of
CRF2 receptors in the hypothalamus. The mechanisms of action
of nesfatin-1 and the pathways that mediate nesfatin-1 induced
satiety are topics that require further investigations. To date, one
study has reported the effects of acute peripheral administration
of nesfatin-1 on food intake which carefully titrated the IC50 of
this effect to 300 nmol/kg bw in rats (Shimizu et al., 2009). How-
ever, at present the receptor(s) for nesfatin-1 both centrally and
peripherally remain unknown and any conclusions of an IC50
based on a single parameter (food intake) can only be construed
as speculation.
We also found that nesfatin-1 reduced average O2
consumption and CO2 production during both dark and
light phases. This resulted in a decrease in RQ, which indicated a
shift in substrate partitioning. In fact, lipid oxidation was signifi-
cantly increased in nesfatin-1-treated animals during both dark
and light phases in the 1 day-study. Interestingly, total EE was
not different between control and nesfatin-1-infused rats, despite
increased spontaneous physical activity during the dark phase in
rats treated with nesfatin-1. This indicates that energy-sparing
mechanisms must have been activated to compensate for the
increased physical activity observed in nesfatin-1 treated rats.
It is also important to consider that nesfatin-1 effects observed
in our study were dependent on the species studied, mode of
delivery, and the doses tested.
A potential explanation for the increased dark-phase physical
activity could reside in the fact that nesfatin-1 treatment elic-
its behaviors including anxiety and fear (Merali et al., 2008). In
fact, Yosten and Samson (2009) have reported that acute central
administration of nesfatin-1 causes hyperactivity that recovers
to normal levels after 15min and then progresses into a phase
of inactivity (Yosten and Samson, 2009). Our findings are in
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FIGURE 7 | Fasting for 18h reduces NUCB2 mRNA expression in the
brain and stomach (A) of rats. Re-feeding for 4 h normalized NUCB2
mRNA expression in the brain (A). Serum NUCB2 levels were lower in rats
fasted for 18 h (B). There was a post-prandial increase in serum
nesfatin-1/NUCB2 levels in rats 3 h after the beginning of dark phase (C). All
data are presented as means ± SEM. n = samples from six rats analyzed in
duplicates. *P < 0.05 compared to fed rats or at 6 p.m., **P < 0.01
compared to unfed rats.
agreement with these studies. Additionally, it has been found that
nesfatin-1 is co-expressed with CRF in brain (Brailoiu et al., 2007;
Fort et al., 2008). CRF expression alters responses to stress and
regulates energy metabolism (Koob and Heinrichs, 1999; Kohno
et al., 2008). Also, it has been reported that nesfatin-1 expres-
sion is mediated by alpha-MSH, and alpha-MSH administration
provokes behaviors related to anxiety and fear (Merali et al.,
2008). Therefore, it is possible that peripheral nesfatin-1 infu-
sion exerted locomotor andmetabolic effects via CRF and a-MSH
signaling pathways in the brain.
Some results, especially those pertaining to food intake and
feeding bouts in our long-term (7 day) study are very similar to
the findings from the short-term (1 day) study. It was observed
that nesfatin-1 suppresses food intake, average size of feeding
bouts similar to findings of Goebel et al. (2011) and Stengel et al.
(2012), and increases total activity even after 7 days of chronic
infusion of nesfatin-1. In addition, the previous differences
observed in RQ in the short-term study were transient, since they
were not observed during the end of the long-term study. How-
ever, we did observe a consistent decrease inO2 consumption and
CO2 production during the long-term study, which was specific
to the light phase. This observation is also consistent with acti-
vation of energy sparing mechanisms and overall reduction of
energy expenditure observed during the light phase in nesfatin-1
treated animals. In this scenario, it is possible that the sustained
increase in the physical activity of nesfatin-1 treated rats may be
masking potential differences in these variables during the dark
phase.
Previously published results indicate that nesfatin-1 is reduced
in circulation and in the regions of brain during food depri-
vation. We determined the NUCB2 mRNA in the whole brain,
which encompasses a pool of abundant sources of nesfatin-1,
and measured nesfatin-1 in serum collected from rat in various
feeding conditions. It was found that food deprivation for 24 h
causes a reduction in NUCB2 mRNA in the brain and stomach
of rats, while re-feeding normalized NUCB2 mRNA expression
in these tissues. Our data are in agreement with previous reports
that 24-h of fasting downregulates NUCB2 mRNA expression in
the stomach (Stengel et al., 2008; Gonzalez et al., 2011; Konc-
zol et al., 2012; Wernecke et al., 2014) and in the PVN of rats
(Oh-I et al., 2006). Fasting causes an urge to eat and during this,
orexigenic an anorexigens signals are upregulated and downreg-
ulated, respectively. We observed that the reduction in NUCB2
mRNA expression was also followed by a corresponding decrease
in circulating levels of nesfatin-1 in rats deprived of food for 24 h.
These results confirm recent findings that plasma nesfatin-1 lev-
els are significantly reduced after a 24 h fast (Stengel et al., 2009).
In this study, Sprague Dawley rats were used and the circulat-
ing levels of nesfatin-1 was detected at 500 pg/mL. We found
3–5 ng/mL nesfatin-1 in Fischer 344 rats. These results are similar
to what we have reported previously in fed Fischer 344 rats. It also
agrees with the amount of nesfatin-1 detected by the nesfatin-
1 ELISA manufacturer in undiluted plasma samples from rats.
There are possible species and/or strain specific changes in
circulating nesfatin-1. In addition, we also found elevated levels
of NUCB2 in the circulation during the dark phase, 3 h (2200 h)
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in to the phase where the rats eat. These results strengthen the
notion that nesfatin-1 is an endogenous, meal responsive anorex-
igen, and that the synthesis and release of this novel peptide are
regulated by the metabolic status of the organism. It is possible
that the antibody used in the ELISA detects both nesfatin-1 and
its precursor forms. It is also unknown what percentage of the
total measured NUCB2/nesfatin-1 immunoreactivity indeed rep-
resents nesfatin-1. Several other gut hormones, especially satiety
peptides including CCK (Dockray, 2004), GLP-1 and PYY (Mur-
phy et al., 2006) are released in a meal-sensitive fashion (Murphy
and Bloom, 2006;Murphy et al., 2006). A postprandial increase in
NUCB2 mRNA and circulating protein found in our studies fur-
ther indicates that nesfatin-1 is released in response to nutrients.
Whether nesfatin-1 is stimulated by diets and nutrients that con-
stitute diets warrant future consideration. The abundant expres-
sion of NUCB2 in the gastrointestinal tract and its secretory pro-
file similar to several other gut-derived satiety peptides reinforce
the possibility that nesfatin-1 is an endogenous satiety signal.
Collectively, our results provide compelling evidence that
nesfatin-1 is an anorexigen that influences various aspects of
feeding and metabolism in rats. It highlights that the endogenous
nesfatin-1 and its mRNA profiles befit an anorexigenic peptide
in the strain of rats used here. The postprandial increase, and
food deprivation based reduction in NUCB2 mRNA expression
and circulating levels of NUCB2/nesfatin-1, all are suggestive
of a meal responsive synthesis and secretion of this anorexigen.
We found that peripheral administration of nesfatin-1 reduces
feeding and increases physical activity in the dark phase without
affecting body weight and fat mass, even after prolonged infusion.
These effects are possibly dependent on the peptide dose, route
of administration and animal strain, and are likely linked to the
milieu of endocrine regulators targeted by nesfatin-1 in the dark
vs. light phase. Further studies are required to distinguish doses
that have appetite inhibitory vs. fat influencing effects alone,
and the mechanisms that mediate such effects. Future research
should focus on unraveling central and peripheral target sites,
as well as the intracellular mechanisms by which nesfatin-1 elic-
its its metabolic actions. In addition, the peptidergic pathways
that mediate the anorectic effects of nesfatin-1 also need to be
studied.
Author contributions
Conception and design of the experiments were done by SM
and SU. SM, RG, RC, and SU were involved in the collec-
tion, analysis and interpretation of data. SM, RG, RC, and SU
drafted the article or revised it critically for important intellectual
content.
Acknowledgments
This work is supported by an operating grant from the Canadian
Institutes of Health Research (CIHR) to SU, an Establishment
Grant from the Saskatchewan Health Research Foundation
(SHRF) to SU, and the Canada Foundation for Innovation
(CFI) – Leaders Opportunities Fund grants to SU and RBC. SU
and RBC are recipients of the CIHR New Investigator Award.
RG is a recipient of the Ontario Graduate Scholarship. We
express our sincere thanks to Ms. Mandeep Gaidhu and Dr.
Sergiu Feduic for their help and advice with the use of the
CLAMS.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fcell.2015.
00022/abstract
References
Abbott, C. R., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R., Broad-
head, L. L., et al. (2006). The importance of acclimatisation and habitua-
tion to experimental conditions when investigating the anorectic effects of
gastrointestinal hormones in the rat. Int. J. Obes. (Lond). 30, 288–292. doi:
10.1038/sj.ijo.0803137
Atsuchi, K., Asakawa, A., Ushikai, M., Ataka, K., Tsai, M., Koyama, K.,
et al. (2010). Centrally administered nesfatin-1 inhibits feeding behaviour
and gastroduodenal motility in mice. Neuroreport 21, 1008–1011. doi:
10.1097/WNR.0b013e32833f7b96
Brailoiu, G. C., Dun, S. L., Brailoiu, E., Inan, S., Yang, J., Chang, J. K., et al.
(2007). Nesfatin-1: distribution and interaction with a G protein-coupled
receptor in the rat brain. Endocrinology 148, 5088–5094. doi: 10.1210/en.200
7-0701
Chen, X., Dong, J., and Jiang, Z. Y. (2012). Nesfatin-1 influences the excitability of
glucosensing neurons in the hypothalamic nuclei and inhibits the food intake.
Regul. Pept. 177, 21–26. doi: 10.1016/j.regpep.2012.04.003
Dockray, G. (2004). Gut endocrine secretions and their relevance to sati-
ety. Curr. Opin. Pharmacol. 4, 557–560. doi: 10.1016/j.coph.2004.
05.005
Dong, J., Guan, H. Z., Jiangm, Z. Y., and Chen, X. (2014). Nesfatin-1 influences the
excitability of glucosensing neurons in the dorsal vagal complex and inhibits
food intake. PLoS ONE 9:e98967. doi: 10.1371/journal.pone.0098967
Foo, K. S., Brismar, H., and Broberger, C. (2008). Distribution and neuropeptide
coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat
CNS. Neuroscience 156, 563–579. doi: 10.1016/j.neuroscience.2008.07.054
Fort, P., Salvert, D., Hanriot, L., Jego, S., Shimizu, H., Hashimoto, K., et al.
(2008). The satiety molecule nesfatin-1 is co-expressed with melanin concen-
trating hormone in tuberal hypothalamic neurons of the rat. Neuroscience 155,
174–181. doi: 10.1016/j.neuroscience.2008.05.035
Goebel, M., Stengel, A., Wang, L., Lambrecht, N. W., and Tache, Y. (2009).
Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei.
Neurosci. Lett. 452, 241–246. doi: 10.1016/j.neulet.2009.01.064
Goebel, M., Stengel, A., Wang, L., and Tache, Y. (2011). Central nesfatin-1 reduces
the nocturnal food intake in mice by reducing meal size and increasing
inter-meal intervals. Peptides 32, 36–43. doi: 10.1016/j.peptides.2010.09.027
Gonzalez, R., Mohan, H., and Unniappan, S. (2012). Nucleobindins: bioactive pre-
cursor proteins encoding putative endocrine factors? Gen. Comp. Endocrinol.
176, 341–346. doi: 10.1016/j.ygcen.2011.11.021
Gotoh, K., Masaki, T., Chiba, S., Ando, H., Shimasaki, T., Mitsutomi, K., et al.
(2013). Nesfatin-1, corticotropin-releasing hormone, thyrotropin-releasing
hormone, and neuronal histamine interact in the hypothalamus to regulate
feeding behavior. J. Neurochem. 124, 90–99. doi: 10.1111/jnc.break12066
Gonzalez, R., Perry, R. L., Gao, X., Gaidhu, M. P., Tsushia, R. G., Ceddia, R. B., et al.
(2011). Nutrient responsive nesfatin-1 regulates energy balance and induces
glucose-stimulated insulin secretion in rats. Endocrinology 152, 3628–3637. doi:
10.1210/en.2010-1471
Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 April 2015 | Volume 3 | Article 22
Mortazavi et al. Nesfatin-1 modulates metabolism of rats
Iwasaki, Y., Nakabayashi, H., Kakei, M., Shimizu, H., Mori, M., and Yada, T. (2009).
Nesfatin-1 evokes Ca2+ signaling in isolated vagal afferent neurons via Ca2+
influx throughN-type channels. Biochem. Biophys. Res. Commun. 390, 958–962.
doi: 10.1016/j.bbrc.2009.10.085
Kohno, D., Nakata, M., Maejima, Y., Shimizu, H., Sedbazar, U., Yoshida, N.,
et al. (2008). Nesfatin-1 neurons in paraventricular and supraoptic nuclei of
the rat hypothalamus coexpress oxytocin and vasopressin and are activated by
refeeding. Endocrinology 149, 1295–1301. doi: 10.1210/en.2007-1276
Konczol, K., Pinter, O., Ferenczi, S., Varqa, J., Kovacs, K., Palkovits, M., et al.
(2012). nesfatin-1 exerts long-term effect on food intake and body temperature.
Int. J. Obes. 36, 1514–1521. doi: 10.1038/ijo.2012.2
Koob, G. F., and Heinrichs, S. C. (1999). A role for corticotropin releasing factor
and urocortin in behavioral responses to stressors. Brain Res. 848, 141–152. doi:
10.1016/S0006-8993(99)01991-5
Li, Z., Gao, L., Tang, H., Yin, Y., Xiang, X., Li, Y., et al. (2013). Peripheral effects
of nesfatin-1 on glucose homeostasis. PLoS ONE 8:e71513. doi: 10.1371/jour-
nal.pone.0071513
Merali, Z., Cayer, C., Kent, P., and Anisman, H. (2008). Nesfatin-1 increases
anxiety-and fear-related behaviors in the rat. Psychopharmacology 201,
115–123. doi: 10.1007/s00213-008-1252-2
Mohan, H., and Unniappan, S. (2013). Phylogenetic aspects of
nucleobindin-2/nesfatin-1. Curr. Pharm. Des. 19, 6929–6934. doi:
10.2174/138161281939131127124149
Murphy, K. G., and Bloom, S. R. (2006). Gut hormones and the regu-
lation of energy homeostasis. Nature 444, 854–859. doi: 10.1038/nature
05484
Murphy, K. G., Dhillo, W. S., and Bloom, S. R. (2006). Gut peptides in the reg-
ulation of food intake and energy homeostasis. Endocr. Rev. 27, 719–727. doi:
10.1210/er.2006-0028
Oh-I, S., Shimizu, H., Satoh, T., Okada, S., Adachi, S., Inoue, K., et al. (2006). Iden-
tification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443,
709–712. doi: 10.1038/nature05162
Pan, W., Hsuchou, H., and Kastin, A. J. (2007). Nesfatin-1 crosses the
blood-brain barrier without saturation. Peptides 28, 2223–2228. doi:
10.1016/j.peptides.2007.09.005
Price, T. O., Samsonm, W. K., Niehoff, M. L., and Banks, W. A. (2007). Permeabil-
ity of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 28,
2372–2381. doi: 10.1016/j.peptides.2007.10.008
Shimizu, H., Oh, I. S., Hashimoto, K., Nakata, M., Yamamoto, S., Yoshida, N.,
et al. (2009). Peripheral administration of nesfatin-1 reduces food intake in
mice: the leptin-independent mechanism. Endocrinology 150, 662–671. doi:
10.1210/en.2008-0598
Stengel, A., Goebel, M., Wang, L., Rivier, J., Kobelt, P., Monnikes, H., et al. (2009).
Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats:
differential role of corticotropin-releasing factor2 receptor. Endocrinology 150,
4911–4919. doi: 10.1210/en.2009-0578
Stengel, A., Goebel, M., Yakubov, I., Wang, L., Witcher, D., Coskun, T., et al.
(2008). Identification and characterization of nesfatin-1 immunoreactivity in
endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150,
232–238. doi: 10.1210/en.2008-0747
Stengel, A., Goebel-Stengel, M., Wang, L., Kato, I., Mori, M., and Tache, Y. (2012).
Nesfatin-1(30-59) but not the N- and C-terminal fragments, nesfatin-1(1-29)
and nesfatin-1 (60-82) injected intracerebroventricularly decreases dark phase
food intake by increasing inter-meal intervals in mice. Peptides 35, 143–148.
doi: 10.1016/j.peptides.2012.03.015
Unniappan, S., and Kieffer, T. J. (2008). Leptin extends the anorectic effects
of chronic PYY(3-36) administration in ad libitum-fed rats. Am. J. Phys-
iol. Regul. Integr. Comp. Physiol. 295, R51–R58. doi: 10.1152/ajpregu.002
34.2007
Unniappan, S., McIntosh, C. H., Demuth, H. U., Heiser, U., Wolf, R., and Kieffer,
T. J. (2006). Effects of dipeptidyl peptidase IV on the satiety actions of peptide
YY. Diabetologia 49, 1915–1923. doi: 10.1007/s00125-006-0310-8
Wernecke, K., Lamprecht, I., Johren, O., Lehnert, H., and Schulz, C. (2014).
Nesfatin-1 increases energy expenditure and reduces food intake in rats.Obesity
22, 1662–1668. doi: 10.1002/oby.20736
Yosten, G. L., and Samson, W. K. (2009). Nesfatin-1 exerts cardiovascular
actions in brain: possible interaction with the central melanocortin sys-
tem. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R330–R336. doi:
10.1152/ajpregu.90867.2008
Yosten, G. L., and Samson, W. K. (2010). The anorexigenic and hypertensive
effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor
antagonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1642–R1647. doi:
10.1152/ajpregu.00804.2009
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Mortazavi, Gonzalez, Ceddia and Unniappan. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 April 2015 | Volume 3 | Article 22
